keyword
MENU ▼
Read by QxMD icon Read
search

Immune-hematology | Page 2

keyword
https://read.qxmd.com/read/22986588/effects-of-dietary-supplementation-of-inosine-monophosphate-on-growth-performance-innate-immunity-and-disease-resistance-of-olive-flounder-paralichthys-olivaceus
#21
Jin-Woo Song, Se-Jin Lim, Kyeong-Jun Lee
This study was investigated to examine the effects of dietary inosine monophosphate (IMP) supplementation on growth performance, feed utilization, innate immunity, hematological parameters and disease resistance of juvenile olive flounder. Five experimental diets were formulated to contain IMP at levels of 0, 0.1, 0.2, 0.4 and 1.0%. All diets were maintained isonitrogenous (48% crude protein) and isocaloric (20.7 MJ/kg diet). Triplicate groups of olive flounder (initial body weight, 7.5 ± 0.02 g) were fed one of the experimental diets to apparent satiation (twice a day) for 14 weeks...
October 2012: Fish & Shellfish Immunology
https://read.qxmd.com/read/22965935/interstitial-deletion-of-11q-implicating-the-kirrel3-gene-in-the-neurocognitive-delay-associated-with-jacobsen-syndrome
#22
Andrea Guerin, Dimitri J Stavropoulos, Yaser Diab, Sébastien Chénier, Hilary Christensen, Walter H A Kahr, Riyana Babul-Hirji, David Chitayat
Jacobsen syndrome (JS) is a rare contiguous gene disorder characterized by a deletion within the distal part of the long arm of chromosome 11 ranging in size from 7 to 20 Mb. The clinical findings include characteristic dysmorphic features, growth and psychomotor delays and developmental anomalies involving the brain, eyes, heart, kidneys, immune, hematologic, endocrine, and gastrointestinal systems. The majority of cases are due to a terminal deletion of 11q; however interstitial deletions have also been reported...
October 2012: American Journal of Medical Genetics. Part A
https://read.qxmd.com/read/22712287/-the-individual-selection-of-erythrocytes-for-regional-clinics
#23
N G Filina, T B Kolotvina, E B Zhiburt
The article deals with the results of work of Krasnoyarsk kray blood center immune hematologic laboratory concerning selection of erythrocytes in 2003-2010. In Krasnoyarsk kray, the portion of transfusions of individually selected erythrocytes increases and reached 31.9%. The setting up of register of donors typed by Ab0 and Rhesus systems makes it possible to implement effectively the individual selection of erythrocytes in optimal time-frame and in amount needed in clinics.
March 2012: Klinicheskaia Laboratornaia Diagnostika
https://read.qxmd.com/read/22653800/treatment-of-immune-thrombocytopenia-with-intravenous-immunoglobulin-and-insights-for-other-diseases-a-historical-review
#24
REVIEW
Paul Imbach
Since 1946 the development of fractionation and purification methods of human plasma led to biologic immunoglobulin for intravenous use (IVIG). In 1980 a child with refractory immune thrombocytopenia (ITP), bleeding and secondary hypogammaglobulinaemia due to long term immunosuppressive treatment got IVIG. His platelet counts dramatically increased. In 13 consecutive children with ITP, but without hypogammaglobulinaemia, similar rapid platelet increases were observed and confirmed in a controlled, multicentre study...
2012: Swiss Medical Weekly
https://read.qxmd.com/read/21488896/clinical-tolerance-in-allogeneic-hematopoietic-stem-cell-transplantation
#25
REVIEW
Maria-Grazia Roncarolo, Silvia Gregori, Barbarella Lucarelli, Fabio Ciceri, Rosa Bacchetta
Allogeneic hematopoietic stem cell transplantation (HSCT) has been a curative therapeutic option for a wide range of immune hematologic malignant and non-malignant disorders including genetic diseases and inborn errors. Once in the host, allogeneic transplanted cells have not only to ensure myeloid repopulation and immunological reconstitution but also to acquire tolerance to host human leukocyte antigens via central or peripheral mechanisms. Peripheral tolerance after allogeneic HSCT depends on several regulatory mechanisms aimed at blocking alloimmune reactivity while preserving immune responses to pathogens and tumor antigens...
May 2011: Immunological Reviews
https://read.qxmd.com/read/20156760/safety-of-laboratory-analyzers-for-infection-testing-results-of-the-market-surveillance-by-the-bfarm-until-end-2007
#26
R Siekmeier, J Halbauer, W Mientus, D Wetzel
The European Directive 98/79/EC on in vitro diagnostic medical devices (IVD) stipulates the marketing and post market surveillance of IVD in the European Economic Area. In cases of issues and field corrective actions, the manufacturers have to inform the responsible Competent Authorities (CA). In Germany, the Federal Institute for Drugs and Medical Devices (BfArM) is the responsible CA for most IVD, with a small subset of IVD for immune hematological and infectiological testing as well as tissue typing as specified in Annex II of the Directive, being within the responsibility of the Paul-Ehrlich-Institute (PEI)...
December 7, 2009: European Journal of Medical Research
https://read.qxmd.com/read/19218690/safety-of-reagents-for-infection-testing-results-of-the-market-surveillance-by-the-federal-institute-for-drugs-and-medicinal-devices-until-end-2006
#27
R Siekmeier, J Halbauer, W Mientus, D Wetzel
The European Directive 98/79/EC on in vitro diagnostic medical devices (IVD) stipulates the marketing and post market surveillance of IVD in the European Economic Area. In cases of issues and field corrective actions, the manufacturers have to inform the responsible Competent Authorities (CA). In Germany, the Federal Institute for Drugs and Medical Devices (BfArM) is the responsible CA for most IVD, with a small subset of IVD for immune hematological and infection testing as well as tissue typing as specified in Annex II of the Directive, being within the responsibility of the Paul-Ehrlich-Institute (PEI)...
December 2008: Journal of Physiology and Pharmacology: An Official Journal of the Polish Physiological Society
https://read.qxmd.com/read/18691115/targeting-cyclooxygenase-2-in-hematological-malignancies-rationale-and-promise
#28
REVIEW
M P Bernard, S Bancos, P J Sime, R P Phipps
There is much interest in the potential use of Cox-2 selective inhibitors in combination with other cancer therapeutics. Malignancies of hematopoietic and non-hematopoietic origin often have increased expression of cyclooxygenase-2 (Cox-2), a key modulator of inflammation. For example, hematological malignancies such as chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma and multiple myeloma often highly express Cox-2, which correlates with poor patient prognosis...
2008: Current Pharmaceutical Design
https://read.qxmd.com/read/18259714/-are-test-systems-for-diagnostics-of-infectious-diseases-safe-experiences-of-the-bfarm-based-on-all-notifications-received-until-end-of-2005
#29
COMPARATIVE STUDY
R Siekmeier, J Lütz, D Wetzel
The European Directive 98/79/EC for in vitro diagnostic medical devices (IVD) regulates the marketing and post marketing surveillance of IVD in the European Economic Area. Manufacturers have to inform the responsible Competent Authorities about incidents and field corrective actions related to IVD. In Germany, the Federal Institute for Drugs and Medical Devices (BfArM) is the responsible Competent Authority for most IVD, while a small subset of IVD, specified in Annex II of the Directive 98/79/EC for immune hematological and infectiological testing as well as tissue typing, is under the responsibility of the Paul-Ehrlich-Institute (PEI)...
February 2008: Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
https://read.qxmd.com/read/17924068/-safety-of-in-vitro-diagnostics-used-in-transfusion-medicine-experience-of-the-bfarm-until-end-2005
#30
R Siekmeier, J Halbauer, D Wetzel
The European Directive 98/79/EC on in-vitro diagnostic medical devices (IVD) stipulates the marketing and post marketing surveillance of IVD in the European Economic Area. In cases of incidents and field corrective actions related to IVD, manufacturers have to inform the responsible Competent Authorities. In Germany, the Federal Institute for Drugs and Medical Devices (BfArM) is the responsible Competent Authority for most IVD. Only a small subset of IVD for immune hematological and infectiological testing, as well as tissue typing specified in Annex II of the Directive, is under the responsibility of the Paul-Ehrlich-Institute (PEI)...
October 2007: Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
https://read.qxmd.com/read/17149661/-are-blood-glucose-analyzers-safe-experiences-of-the-bfarm-based-on-all-notifications-received-until-end-of-2005
#31
R Siekmeier, J Lütz
Since implementation of the Directive 98/79/EC of the European Parliament and of the Council on in vitro Diagnostic Medical Devices (IVD Directive), issues and field corrective actions on in vitro diagnostic medical devices (IVDMD) have to be reported to the national competent authorities. In Germany these are the BfArM and the Paul Ehrlich Institute; the latter is responsible for Annex II products used for immune hematology, tissue typing and infectiology testing. Between the beginning of 1999 and the end of 2005 BfArM received n=653 notifications on IVDMD...
December 2006: Bundesgesundheitsblatt, Gesundheitsforschung, Gesundheitsschutz
https://read.qxmd.com/read/15536153/whim-syndromes-with-different-genetic-anomalies-are-accounted-for-by-impaired-cxcr4-desensitization-to-cxcl12
#32
Karl Balabanian, Bernard Lagane, José Luis Pablos, Lysiane Laurent, Thierry Planchenault, Olivier Verola, Celeste Lebbe, Delphine Kerob, Alain Dupuy, Olivier Hermine, Jean-François Nicolas, Véronique Latger-Cannard, Danièle Bensoussan, Pierre Bordigoni, Françoise Baleux, Françoise Le Deist, Jean-Louis Virelizier, Fernando Arenzana-Seisdedos, Françoise Bachelerie
The WHIM syndrome is a rare immunodeficiency disorder characterized by warts, hypogammaglobulinemia, infections, and myelokathexis. Dominant heterozygous mutations of the gene encoding CXCR4, a G-protein-coupled receptor with a unique ligand, CXCL12, have been associated with this pathology. We studied patients belonging to 3 different pedigrees. Two siblings inherited a CXCR4 mutation encoding a novel C-terminally truncated receptor. Two unrelated patients were found to bear a wild-type CXCR4 open reading frame...
March 15, 2005: Blood
https://read.qxmd.com/read/15456917/endocrine-disruption-in-adolescence-immunologic-hematologic-and-bone-effects-in-monkeys
#33
Mari S Golub, Casey E Hogrefe, Stacey L Germann, Christopher P Jerome
Environmental contaminants with estrogenic properties have the potential to alter pubertal development. In addition to the reproductive system, other systems that mature under the influence of estrogen could be affected. This study examined the effect on immune, hematologic, and bone mass parameters of treatment with estrogenic agents (methoxychlor, MXC, 25 and 50 mg/kg/day; diethylstilbestrol, DES, 0.5 mg/kg/day) given in the peripubertal period to female rhesus monkeys. DES had striking effects on several parameters assessed measures CBC and clinical chemistry including hematocrit, hemoglobin, serum albumin, liver transaminases, and lipids...
December 2004: Toxicological Sciences: An Official Journal of the Society of Toxicology
https://read.qxmd.com/read/15239832/evolutionary-conservation-and-selection-of-human-disease-gene-orthologs-in-the-rat-and-mouse-genomes
#34
COMPARATIVE STUDY
Hui Huang, Eitan E Winter, Huajun Wang, Keith G Weinstock, Heming Xing, Leo Goodstadt, Peter D Stenson, David N Cooper, Douglas Smith, M Mar Albà, Chris P Ponting, Kim Fechtel
BACKGROUND: Model organisms have contributed substantially to our understanding of the etiology of human disease as well as having assisted with the development of new treatment modalities. The availability of the human, mouse and, most recently, the rat genome sequences now permit the comprehensive investigation of the rodent orthologs of genes associated with human disease. Here, we investigate whether human disease genes differ significantly from their rodent orthologs with respect to their overall levels of conservation and their rates of evolutionary change...
2004: Genome Biology
https://read.qxmd.com/read/13285815/-study-of-immune-hematology-in-werlhof-s-disease-case-report
#35
A AUFDERMAUR, W MEYER
No abstract text is available yet for this article.
November 1955: Helvetica Medica Acta
https://read.qxmd.com/read/12921129/plasmapheresis-in-immune-hematology-review-of-clinical-outcome-data-with-respect-to-evidence-based-medicine-and-clinical-experience
#36
REVIEW
Hans von Baeyer
The objective of this paper is to assess the role of plasmapheresis in immune hematology by reviewing published clinical outcome data and narrative review articles. This information will be used to define evidence levels for appraisal of the efficacy and rank of plasmapheresis among other management options. This evidence-based strategy conforms to the concepts of the American Society of Hematology (ASH). as put forward in 1996 in the context of immune thrombocytopenia (ITP) treatment. The term 'experimental' is used to describe indications where the only scientific evidence of the efficacy of plasmapheresis consists of pathophysiological reasoning and empiric clinical findings...
February 2003: Therapeutic Apheresis and Dialysis
https://read.qxmd.com/read/11732111/-karl-landsteiner
#37
H Gröger
Karl Landsteiner received the Nobel Prize for Medicine in 1930. He worked in Vienna, The Hague and New York, making fundamental contributions in the field of immune hematology (blood groups and Rhesus factor), syphilis (visualising spirochetes in the dark field) and poliomyelitis (viral genesis). In particular, his findings in the general field of serology and immunology (haptens, specificity of antigens) have not lost any of their significance and are valid to this day.
October 30, 2001: Wiener Klinische Wochenschrift
https://read.qxmd.com/read/11455342/relationships-of-climatic-data-to-immune-and-hematologic-variables-in-normal-human
#38
Michael Maes, Frans De Meyer
OBJECTIVES: The purpose of this study was to examine the relationships between climatic and immune or hematologic variables in the peripheral blood of normal human. METHODS: Twenty-six normal volunteers gave blood samples monthly during one calendar year for flow cytometric assays of peripheral blood mononuclear cells (PBMC) and assays of red blood cell (RBC)- and platelet-related variables. Time relationships between the weather and immune or hematologic variables were investigated by means of multiple regression and bivariate cosinor analyses...
2000: Neuro Endocrinology Letters
https://read.qxmd.com/read/11421298/intravenous-gammglobulin-associated-acute-renal-failure
#39
N Gupta, I Ahmed, S Nissel-Horowitz, D Patel, B Mehrotra
Intravenous gammaglobulins are used for the treatment of various auto-immune hematological disorders. Renal failure is a relatively rare, but an increasingly recognized side effect of gammaglobulin therapy. Although the renal failure is usually reversible, renal replacement therapy is required occasionally. A high index of suspicion, early recognition and appropriate intervention can prevent this complication. We herewith describe two patients with an immune hematological disorder, who developed acute renal failure after treatment with intravenous gammaglobulins...
February 2001: American Journal of Hematology
https://read.qxmd.com/read/11157013/pilot-trial-of-interleukin-2-with-granulocyte-colony-stimulating-factor-for-the-mobilization-of-progenitor-cells-in-advanced-breast-cancer-patients-undergoing-high-dose-chemotherapy-expansion-of-immune-effectors-within-the-stem-cell-graft-and-post-stem-cell
#40
J A Sosman, P Stiff, S M Moss, P Sorokin, B Martone, R Bayer, K van Besien, S Devine, W Stock, D Peace, Y Chen, C Long, D Gustin, M Viana, R Hoffman
PURPOSE: To evaluate whether administration of interleukin-2 (IL-2) with granulocyte colony-stimulating factor (G-CSF) improves mobilization of immune effector cells into the stem-cell graft of patients undergoing high-dose chemotherapy and autografting. PATIENTS AND METHODS: We performed a trial of stem-cell mobilization with IL-2 and G-CSF in advanced breast cancer patients receiving high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin and stem cells followed by IL-2...
February 1, 2001: Journal of Clinical Oncology
keyword
keyword
168406
2
3
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"